Open Access

IL‑6 inhibitors effectively reverse post‑infarction cardiac injury and ischemic myocardial remodeling via the TGF‑β1/Smad3 signaling pathway

  • Authors:
    • Jiahong Wang
    • Minghong Wang
    • Xiancheng Lu
    • Yi Zhang
    • Siliang Zeng
    • Xin Pan
    • Yimeng Zhou
    • Hui Wang
    • Nannan Chen
    • Fengfeng Cai
    • Ewelina Biskup
  • View Affiliations

  • Published online on: July 18, 2022     https://doi.org/10.3892/etm.2022.11513
  • Article Number: 576
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Approximately one in four myocardial infarctions occur in older patients. The majority of therapeutic advances are either not appropriate or not tested in elderly patients. The main reasons for deviating from the guidelines are justified concerns regarding the effectiveness of the recommended forms of therapy, fear of adverse drug reactions and ethical concerns. Targeting interleukin 6 (IL‑6) for ventricular remodeling after cardiovascular damage is a feasible alternative to standard polypharmaceutics, but the underlying molecular mechanisms are not well understood. Continuous activation of the IL‑6‑associated cytokine receptor gp130 leads to cardiomyopathic hypertrophy. TGFβ1 is involved in forming fibrosis in various organs, and its overexpression can cause myocardial hypertrophy and fibrosis. Il‑6 has been hypothesized to be indirectly involved in cardiac remodeling via the TGFβ1/Smad signaling transduction pathway. In the present study, a rat model of acute myocardial ischemia, IL‑6 and IL‑6 receptor blockers were injected directly into the necrotic myocardium. Changes in cardiac function, myocardial infarction area, myocardial collagen, necrotic myocardial fibrosis and levels of TGFβ1, IL‑6 and MMP2/9 were quantified in myocardial tissue fibrosis by ELISA. The present study demonstrated that IL‑6 stimulated myocardial fibrosis through the TGFβ1‑Smad‑MM2/9 signaling transduction pathway. Overall, this provided a solid foundation for understanding the relationship between IL‑6 and ventricular remodeling.

Related Articles

Journal Cover

September-2022
Volume 24 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang J, Wang M, Lu X, Zhang Y, Zeng S, Pan X, Zhou Y, Wang H, Chen N, Cai F, Cai F, et al: IL‑6 inhibitors effectively reverse post‑infarction cardiac injury and ischemic myocardial remodeling via the TGF‑β1/Smad3 signaling pathway. Exp Ther Med 24: 576, 2022
APA
Wang, J., Wang, M., Lu, X., Zhang, Y., Zeng, S., Pan, X. ... Biskup, E. (2022). IL‑6 inhibitors effectively reverse post‑infarction cardiac injury and ischemic myocardial remodeling via the TGF‑β1/Smad3 signaling pathway. Experimental and Therapeutic Medicine, 24, 576. https://doi.org/10.3892/etm.2022.11513
MLA
Wang, J., Wang, M., Lu, X., Zhang, Y., Zeng, S., Pan, X., Zhou, Y., Wang, H., Chen, N., Cai, F., Biskup, E."IL‑6 inhibitors effectively reverse post‑infarction cardiac injury and ischemic myocardial remodeling via the TGF‑β1/Smad3 signaling pathway". Experimental and Therapeutic Medicine 24.3 (2022): 576.
Chicago
Wang, J., Wang, M., Lu, X., Zhang, Y., Zeng, S., Pan, X., Zhou, Y., Wang, H., Chen, N., Cai, F., Biskup, E."IL‑6 inhibitors effectively reverse post‑infarction cardiac injury and ischemic myocardial remodeling via the TGF‑β1/Smad3 signaling pathway". Experimental and Therapeutic Medicine 24, no. 3 (2022): 576. https://doi.org/10.3892/etm.2022.11513